Valeur202020212022202320242025TTMFrais de vente, généraux et administratifs68.84 M97.59 M106.9 M121 M142.79 M166.99 M174.41 MRecherche et développement13.02 M16.29 M19.94 M21.04 M24.8 M27.56 M28.41 MRésultat d'exploitation2.37 M-7.85 M-17.06 M-6.46 M4.52 M11.04 M15.77 MTotal des produits hors exploitation672 K272 K1.07 M4.1 M5.99 M6.33 M6.55 MCharges d'intérêts, nettes des intérêts capitalisés13 K4 000366 K600 K614 K630 K637 KRésultat hors exploitation, hors charges d'intérêts665 K216 K609 K3.43 M5.8 M5.75 M5.93 MRevenus/dépenses exceptionnels-6 00052 K95 K64 K195 K-44 K-15 KRésultat avant impôts3.04 M-7.58 M-15.99 M-2.37 M10.51 M17.38 M15.12 MPart des actionnaires dans le résultat———————Impôts180 K-111 K721 K814 K148 K859 K—Intérêts ne donnant pas le contrôle / intérêts minoritaires———————Autres produits/charges après impôts—-7 000-22 K-39 K-43 K-13 K-30 KRésultat net avant activités abandonnées2.86 M-7.47 M-16.71 M-3.18 M10.36 M16.52 M21.46 MActivités abandonnées———————Résultat net2.86 M-7.47 M-16.71 M-3.18 M10.36 M16.52 M21.46 MAjustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires2.86 M-7.47 M-16.71 M-3.18 M10.36 M16.52 M21.46 MBénéfice par action de base (BPA de base)0.06-0.16-0.35-0.070.210.330.44Bénéfice par action dilué (BPA dilué)0.06-0.16-0.35-0.070.20.320.43Nombre moyen d'actions de base en circulation45.22 M46.47 M47.13 M47.59 M48.85 M50.34 M—Nombre d'actions en circulation après dilution47.28 M46.47 M47.13 M47.59 M51.68 M52.15 M—EBITDA4.75 M-4.85 M-13.08 M-1.83 M10.02 M22.59 M27.9 MEBIT2.37 M-7.85 M-17.06 M-6.46 M4.52 M11.04 M15.77 MCoût des ventes39.95 M50.16 M54.58 M61.94 M65.12 M70.66 M73.49 MAutres coûts des ventes—————1.04 M—Amortissements (flux de trésorerie)2.38 M3 M3.98 M4.63 M5.5 M11.54 M12.13 M
Vericel Corporation - Common Stock
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011. This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before.
In October 2014, the company changed its name from Aastrom Bio to Vericel and relocated its headquarters from Ann Arbor, Michigan to Cambridge, Massachusetts.